|
|
| |
| Articles
by
Rema Raman |
Total Records (
2 ) for
Rema Raman |
|
 |
| |
|
| |
Danielle C. Whitehair
,
Abdullah Sherzai
,
Jennifer Emond
,
Rema Raman
,
Paul S. Aisen
,
Ronald C. Petersen
and
Adam S. Fleisher
|
| |
Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55–90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ε4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ε4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ε4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Conclusions: These findings demonstrate that APOE ε4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ε4 status needs to be accounted for in treatment trials of MCI. |
|
| |
|
| |
Paul S. Aisen
,
Ronald C. Petersen
,
Michael C. Donohue
,
Anthony Gamst
,
Rema Raman
,
Ronald G. Thomas
,
Sarah Walter
,
John Q. Trojanowski
,
Leslie M. Shaw
,
Laurel A. Beckett
,
Clifford R. Jack Jr.
,
William Jagust
,
Arthur W. Toga
,
Andrew J. Saykin
,
John C. Morris
,
Robert C. Green
and
Michael W. Weiner
|
| |
The Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer’s disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations. |
|
|
|
|
| |
|
